Evista (raloxifene HCl tablets, from Eli Lilly) will now be supplied as 30-count blister packs instead of 30-count bottles. Evista will continue to be available in the 100-count and 2000-count bottles.

Evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and/or high risk for invasive breast cancer.

For more information call (800) LillyRx or visit www.evista.com.